Risankizumab for previously treated moderately to severely active Crohn's disease

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 4.68 MB)

  Published:

  17 May 2023

• Final draft guidance consultation committee papers (PDF 995 KB)

  Published:

  17 May 2023